Cargando…
Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/ https://www.ncbi.nlm.nih.gov/pubmed/37123608 http://dx.doi.org/10.1159/000530154 |
_version_ | 1785031676460531712 |
---|---|
author | Batman, Samantha Rauh-Hain, J. Alejandro Grinsfelder, Michaela Onstad Harrison, Ross Avila, Monica Cun, Han How, Jeffrey Andrew Tandon, Nidhi Wang, Xiaohong Hinchcliff, Emily Jazaeri, Amir Anthony Schmeler, Kathleen M. |
author_facet | Batman, Samantha Rauh-Hain, J. Alejandro Grinsfelder, Michaela Onstad Harrison, Ross Avila, Monica Cun, Han How, Jeffrey Andrew Tandon, Nidhi Wang, Xiaohong Hinchcliff, Emily Jazaeri, Amir Anthony Schmeler, Kathleen M. |
author_sort | Batman, Samantha |
collection | PubMed |
description | Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndrome is an autosomal dominant disease that causes MSI-high endometrial cancer. We report a case of a 46-year-old woman with Lynch syndrome and advanced endometrial cancer who experienced progressive disease after treatment with chemotherapy with carboplatin and paclitaxel. She was then treated with single-agent pembrolizumab and had an exceptional response. She was noted to have a significant decrease in the size of a large uterine mass extending into the vagina and vulva, as well as decrease in the size of lymphadenopathy. Data are limited at this time for patients with Lynch syndrome treated with single-agent pembrolizumab. Our case report seeks to add to the body of literature that suggests that this patient population may particularly benefit from this novel therapy. |
format | Online Article Text |
id | pubmed-10134052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-101340522023-04-28 Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report Batman, Samantha Rauh-Hain, J. Alejandro Grinsfelder, Michaela Onstad Harrison, Ross Avila, Monica Cun, Han How, Jeffrey Andrew Tandon, Nidhi Wang, Xiaohong Hinchcliff, Emily Jazaeri, Amir Anthony Schmeler, Kathleen M. Case Rep Oncol Case Report Advanced endometrial cancer is associated with poor outcomes and few treatment options exist. Recently, the US Federal Drug Administration approved pembrolizumab for the treatment of endometrial cancers that are deficient in mismatch repair and have high microsatellite instability (MSI). Lynch syndrome is an autosomal dominant disease that causes MSI-high endometrial cancer. We report a case of a 46-year-old woman with Lynch syndrome and advanced endometrial cancer who experienced progressive disease after treatment with chemotherapy with carboplatin and paclitaxel. She was then treated with single-agent pembrolizumab and had an exceptional response. She was noted to have a significant decrease in the size of a large uterine mass extending into the vagina and vulva, as well as decrease in the size of lymphadenopathy. Data are limited at this time for patients with Lynch syndrome treated with single-agent pembrolizumab. Our case report seeks to add to the body of literature that suggests that this patient population may particularly benefit from this novel therapy. S. Karger AG 2023-04-27 /pmc/articles/PMC10134052/ /pubmed/37123608 http://dx.doi.org/10.1159/000530154 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Batman, Samantha Rauh-Hain, J. Alejandro Grinsfelder, Michaela Onstad Harrison, Ross Avila, Monica Cun, Han How, Jeffrey Andrew Tandon, Nidhi Wang, Xiaohong Hinchcliff, Emily Jazaeri, Amir Anthony Schmeler, Kathleen M. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title | Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title_full | Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title_fullStr | Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title_full_unstemmed | Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title_short | Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report |
title_sort | exceptional response to pembrolizumab for treatment of metastatic chemorefractory endometrial carcinoma in a patient with lynch syndrome: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134052/ https://www.ncbi.nlm.nih.gov/pubmed/37123608 http://dx.doi.org/10.1159/000530154 |
work_keys_str_mv | AT batmansamantha exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT rauhhainjalejandro exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT grinsfeldermichaelaonstad exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT harrisonross exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT avilamonica exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT cunhan exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT howjeffreyandrew exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT tandonnidhi exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT wangxiaohong exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT hinchcliffemily exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT jazaeriamiranthony exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport AT schmelerkathleenm exceptionalresponsetopembrolizumabfortreatmentofmetastaticchemorefractoryendometrialcarcinomainapatientwithlynchsyndromeacasereport |